CBX4 enhances acute monocytic leukemia development via HDAC-mediated suppression of Runx1
A protein overexpressed in monocytic leukemia drives disease through an epigenetic mechanism, emerging as a potential diagnostic and therapeutic target.
CBX4 (a PRC1 component) is overexpressed in AML-M5 patient blood and drives monocytic AML development through HDAC-mediated Runx1 suppression in zebrafish models, identifying a mechanistic link between epigenetic dysregulation and this poor-prognosis AML subtype. CBX4 emerges as a potential diagnostic and therapeutic target for AML-M5, though clinical translation requires substantial further work.
What the study was
- Study design
- Zebrafish transgenic model + human AML-M5 blood sample analysis
- Population
- AML-M5 patients (peripheral blood samples); zebrafish hematopoiesis models
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Communications Biology
Why it surfaced
Novel epigenetic mechanism in AML-M5 with human correlation; early-stage preclinical finding in a poorly characterized AML subtype.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.